Iwata, Hiroji http://orcid.org/0000-0002-0242-4718
Yamamoto, Yutaka
Sakai, Takehiko
Hasegawa, Yoshie
Nakamura, Rikiya
Akabane, Hiromitsu
Ohtani, Shoichiro
Kashiwaba, Masahiro
Taira, Naruto
Toyama, Tatsuya
Fujisawa, Tomomi
Masuda, Norikazu
Shibahara, Yukiko
Sasano, Hironobu
Yamaguchi, Takuhiro
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
https://doi.org/10.1007/s10549-023-06874-7
Funding for this research was provided by:
Comprehensive Support Project for Oncology Research of the Public Health Research Foundation
Article History
Received: 2 November 2022
Accepted: 1 February 2023
First Online: 22 March 2023
Declarations
:
: Hiroji Iwata: Consulting fees: Daichi Sankyo, Chugai, AstraZeneca, Sanofi, Lilly, MSD, Pfizer, and Novartis; Honoraria: Daiichi Sankyo, Chugai, AstraZeneca, Lilly, MSD, and Pfizer; Advisory Board: Daichi Sankyo, Chugai, AstraZeneca, Sanofi, Lilly, MSD, Pfizer, and Novartis. Yutaka Yamamoto: Research Funding: MSD Oncology, Chugai, Eisai, Daiichi Sankyo, Nippon Kayaku, Taiho, AstraZeneca, Takeda, and Pfizer; Honoraria: AstraZeneca, Chugai, Kyowa Kirin, Novartis, Lilly Japan, Pfizer, Daiichi Sankyo, MSD, Taiho, Eisai, Takeda, and Sysmex; Advisory Board: AstraZeneca, Chugai, Novartis, Lilly, Pfizer, Daiichi Sankyo, and MSD; Member of the Board of Directors: Japanese Breast Cancer Society and Japan Breast Cancer Research Group. Shoichiro Ohtani: Honoraria: Chugai, Lilly, Pfizer, AstraZeneca, and Eisai. Masahiro Kashiwaba: Honoraria: Chugai, Kyowa Kirin, Lilly Japan, Shionogi, Taiho, Daiichi Sankyo, Eisai, AstraZeneca, Pfizer, and Novartis. Naruto Taira: Honoraria: Pfizer, AstraZeneca, Eisai, ACTmed, and Kyowa Kirin. Tatsuya Toyama: Honoraria: Chugai, Eisai, Novartis, Takeda, Nippon Kayaku, AstraZeneca, Pfizer, and Lilly. Norikazu Masuda: Research Funding: Chugai, Eli Lilly, AstraZeneca, Pfizer, Daiichi Sankyo, MSD, Eisai, Novartis, Sanofi, Kyowa Kirin, and Nippon Kayaku; Honoraria: Eisai, Novartis, Sanofi, Kyowa Kirin, and Nippon Kayaku; Executive Board: Japan Breast Cancer Research Group; Board of Directors: Japanese Breast Cancer Society. Takuhiro Yamaguchi: Research Funding: Kyowa Kirin, AC Medical, A2 Healthcare, Facet Biotech, Japan Tobacco, Japan Media, Medidata Solutions, Ono, Intellim Corporation, Welby, 3H Medi Solution, Nipro, Hemp Kitchen, Nobori, Puravida Technologies, Medrio, 3H Clinical Trial, Senju Pharmaceutical, Otsuka, Eisai, and ClinChoice; Consulting or Advisory Role: EP Croit, Japan Tobacco, Ono, Kowa Company, Daiichi Sanko, Eisai, Chugai, 3H Clinical Trial, Sonire Therapeutics, Seikagaku Corporation, Otsuka, and Incyte Biosciences; Stock and Other Ownership Interests: STATCOM; Speakers' Bureau: Daiichi Sankyo, Takeda, Mebix, and AstraZeneca. Other authors have nothing to disclose.
: This study complied with the Declaration of Helsinki and the Ethical Guides to Clinical Investigations established by the Ministry of Health, Labour and Welfare. The study protocol and all other forms were approved by the ethics committee or internal review board at each study site.
: Signed informed consent was obtained from each participant before initiating any procedures.
: Not applicable.